Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer

Published:2019-01 Issue:1 Volume:42 Page:56-59
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Cubillo Antonio,Álvarez-Gallego Rafael,Muñoz Manuel,Pond Gregory,Perea Sofía,Sánchez Gema,Martin María,Rodríguez-Pascual Jesús,Garralda Elena,Vega Estela,de Vicente Emilio,Quijano Yolanda,Muñoz César,Ugidos Lisardo,Toledo Rodrigo A.,Hidalgo Manuel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference20 articles.

1. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741;Sanoff;J Clin Oncol,2008

2. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741;Dy;J Clin Oncol,2007

3. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer;Tol;N Engl J Med,2009

4. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study;Fuchs;J Clin Oncol,2007

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;Brain Tumor Pathology;2024-04

2. Construction and validation of a novel angiogenesis pattern to predict prognosis and immunotherapy efficacy in colorectal cancer;Aging;2023-11-07

3. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;2023-10-06

4. Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies;Frontiers in Oncology;2022-01-10

5. Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients’ Outcome;Cancers;2021-03-06